JP2022535816A5 - - Google Patents

Info

Publication number
JP2022535816A5
JP2022535816A5 JP2021571671A JP2021571671A JP2022535816A5 JP 2022535816 A5 JP2022535816 A5 JP 2022535816A5 JP 2021571671 A JP2021571671 A JP 2021571671A JP 2021571671 A JP2021571671 A JP 2021571671A JP 2022535816 A5 JP2022535816 A5 JP 2022535816A5
Authority
JP
Japan
Prior art keywords
polypeptide
cytotoxic agent
collagen
linked
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535816A (ja
JP7680375B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/070113 external-priority patent/WO2020247974A1/en
Publication of JP2022535816A publication Critical patent/JP2022535816A/ja
Publication of JP2022535816A5 publication Critical patent/JP2022535816A5/ja
Priority to JP2025077691A priority Critical patent/JP2025121986A/ja
Application granted granted Critical
Publication of JP7680375B2 publication Critical patent/JP7680375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571671A 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 Active JP7680375B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077691A JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856468P 2019-06-03 2019-06-03
US62/856,468 2019-06-03
PCT/US2020/070113 WO2020247974A1 (en) 2019-06-03 2020-06-03 Methods and compositions for treating cancer with collagen binding drug carriers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077691A Division JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2022535816A JP2022535816A (ja) 2022-08-10
JP2022535816A5 true JP2022535816A5 (cg-RX-API-DMAC7.html) 2023-06-13
JP7680375B2 JP7680375B2 (ja) 2025-05-20

Family

ID=73652058

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571671A Active JP7680375B2 (ja) 2019-06-03 2020-06-03 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物
JP2025077691A Pending JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077691A Pending JP2025121986A (ja) 2019-06-03 2025-05-08 コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物

Country Status (9)

Country Link
US (1) US20220298225A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976111A4 (cg-RX-API-DMAC7.html)
JP (2) JP7680375B2 (cg-RX-API-DMAC7.html)
CN (1) CN114173822B (cg-RX-API-DMAC7.html)
AU (1) AU2020289485A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024438A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144535A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014932A (cg-RX-API-DMAC7.html)
WO (1) WO2020247974A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
WO2024177006A1 (ja) * 2023-02-20 2024-08-29 国立大学法人大阪大学 細胞にタンパク質付着性を付与する細胞デザイナー分子
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
DK3186284T3 (da) * 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
US10420820B2 (en) * 2014-09-29 2019-09-24 Counterpoint Biomedia LLC Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polypeptides
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질

Similar Documents

Publication Publication Date Title
US11833120B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
JP2022542886A5 (cg-RX-API-DMAC7.html)
JP6306596B2 (ja) セリンプロテアーゼ分子および療法
Curnis et al. NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors
JP2025121986A5 (cg-RX-API-DMAC7.html)
JP2020524141A5 (cg-RX-API-DMAC7.html)
EP3145530B1 (en) Trail receptor agonists for treatment of fibrotic diseases
JP2024517871A5 (cg-RX-API-DMAC7.html)
McGonigle et al. Neuropilin-1 drives tumor-specific uptake of chlorotoxin
JP2020509737A5 (cg-RX-API-DMAC7.html)
WO2016186445A1 (ko) 암 세포 표적용 펩타이드 및 이의 용도
CN114173822B (zh) 用胶原结合药物载体治疗癌症的方法和组合物
US20160022776A1 (en) Trail receptor agonists for treatment of fibrotic disease
CN113039194A (zh) 具有免疫调节特性的肽
CN1345336A (zh) 抗体和趋化因子构建物及其在自身免疫疾病治疗中的用途
JP2026048706A5 (cg-RX-API-DMAC7.html)
CA3177566A1 (en) Tnf.alpha. immunoconjugate therapy for the treatment of brain tumors
CN111499762A (zh) 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途
WO2022206881A1 (zh) 核酸自组装介导的adc药物的构建方法及应用
Hao et al. ‘Renovation of old drugs’–can peptide drug conjugates lead the post-ADC era?
Martinez-Torro et al. Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticles
EP0618816B1 (en) Further improvements relating to the radiolabelling of proteins
AU2011287552B2 (en) Antibodies against 6-sulfo-LacNAc-positive human dendritic cells, and their use
EP4587062A1 (en) Isolated targeted delivery system for the treatment of glioma
WO2024133541A1 (en) Isolated targeted delivery system for the treatment of ovarian cancer